A study was then done to present the safety and efficacy of intravitreal implants releasing 0.2mcg/day of fluocinolone acetonide (FAc) in patients which chronic versus nonchronic DME. Chronic was defined as a diagnoses of DME for 3 years or greater while a diagnoses if DME for less than 3 years was characterized as nonchronic.